[1] HPV疫苗临床应用专家共识
[2] Wu EQ,Liu B,Cul JF,et al. Prevalence of type-specific human papillomanvirus and pap results in Chinesewomen:a multi-center,population-based cross-sec-tional study.Cancer Causes Control.2013
[3] 宋祎凡, 刘晓雪, 尹遵栋, 余文周, 曹雷, & 曹玲生等. (2021). 2018-2020年中国9-45岁女性人乳头瘤病毒疫苗估算接种率. 中国疫苗和免疫, 27(5), 6.
[4] 中华预防医学会疫苗与免疫分会. 子宫颈癌等人乳头瘤病毒相关疾病免疫预防专家共识[J]. 中华预防医学杂志, 2019, 53(8):761-803.
[5] Information About the Human Papillomavirus (HPV). WebMD. Accessed April 8, 2022.
[6] Serrano B, de Sanjosé S, Tous S, et al. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer. 2015;51(13):1732-1741. doi:10.1016/j.ejca.2015.06.001
[7] Gu, W., Zhang, P., Zhang, G., Zhou, J., Ding, X., Wang, Q., ... & Zhu, Y. (2020). Importance of HPV in Chinese penile cancer: a contemporary multicenter study. Frontiers in oncology, 1521.
[8] Romanowski, Barbara et al. “Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.” Human vaccines & immunotherapeutics vol. 12,1 (2016): 20-9. doi:10.1080/21645515.2015.1065363
[9] Schwarz TF, Huang LM, Valencia A, et al. A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years. Hum Vaccin Immunother. 2019;15(7-8):1970-1979. doi:10.1080/21645515.2019.1625644
[10] HPV - Vaccine Preventable Diseases Surveillance Manual | CDC. Published April 6, 2022. Accessed April 8, 2022.